Tagged with USA

China Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the company’s unique single-cell technology platform, its open innovation approach, experience with capital markets, and advice for other biotech leaders.   The traditional bulk analysis method is well-established and suited for diseases that are more homogenous, but cancer…

USA Dr Maria T. Millan, president and CEO of the California Institute for Regenerative Medicine (CIRM), shares the Institute’s mission to advance basic and translational research in regenerative medicine in the State of California, their unique funding and operating model, and her perspective on the critical importance of investment in science…

USA Certara’s Ulrich Neumann examines some of the major US market access trends of the past few years, including the innovative financing models required for novel therapies, why cost effectiveness considerations are on the rise, and the impact of the drug policy environment on payer sentiments.   The US reimbursement landscape…

Global David H. Crean summarizes the recent 39th annual J.P. Morgan Healthcare Conference 2021 that was held in a virtual format, noting potential changes in format for future events. Crean does, however, underline the importance of the Conference for industry networking and highlights some of the biopharma topics to watch under…

USA Hours after President Biden was inaugurated on Tuesday 19th January 2021, Dr Janet Woodcock was named as acting commissioner for the Food and Drugs Administration (FDA). “The FDA’s public health work is more critical than ever as we continue to fight this global pandemic… The American people can be certain…

Norway Photodynamic therapy (PDT) firm Photocure is probably Norway’s most significant recent international healthcare success story. CEO Dan Schneider explains how the company was able to action a more effective global commercial strategy and carve out a niche in the relatively uncrowded oncology drug-device combination market.   Despite its technology being…

USA A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to investment and innovation. It also holds a tremendous amount of clout, representing half the world’s healthcare market, and the US healthcare industry itself is…

USA In a recent article for PharmaBoardroom, Objective Capital’s David Crean took a look at the state of US innovation today and its long term sustainability. See below for data on the share of US executives who see innovation as a top priority post-COVID, Global Public Equity Issuance for the Biopharmaceutical…

USA AAM President Dan Leonard highlights the findings of the association’s most recent report and re-states the value proposition of generic and biosimilar drugs in the USA.   AAM’s 2020 access and savings report documenting the savings generated by generic prescription drugs once again trumpets the value proposition of generic and…

USA Rare disease – defined in the US as a disease with a maximum patient population of 200,000 – is perhaps the most salient issue at the nexus of innovation, access, and affordability in the country.   As FDA CDER director Dr Janet Woodcock indicates, “rare diseases have been rising as…

USA With a series of reorganization initiatives, new leaders at the helm and exciting acquisitions, Novartis Oncology has undergone a significant business transformation in the past few years, and if the business unit’s 2019 performance is anything to go by, the efforts have paid off, with net sales reaching USD 14.4…

USA Joe Lewis outlines the key concerns of Deloitte’s pharma clients around manufacturing and supply chain operations in the wake of the COVID-19 pandemic, how companies can come out of the crisis stronger, and highlights some of the major issues surrounding vaccine allocation and deployment.   One of the most common…